Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

American Society of Nephrology
You have accessRestricted Access
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Glenn Chertow, Priya Vart, Niels Jongs, Robert Toto, Jose Luis Gorriz, Fan Fan Hou, John McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur Stefánsson, Anna Maria Langkilde, David Wheeler and Hiddo Heerspink
JASN July 2021, ASN.2021020167; DOI: https://doi.org/10.1681/ASN.2021020167
Glenn Chertow
G Chertow, Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, United States
Search for this author on this site
John McMurray
J McMurray, University of Glasgow Institute of Cardiovascular and Medical Sciences, Glasgow, United Kingdom of Great Britain and Northern Ireland
Search for this author on this site
David Wheeler
D Wheeler, Department of Renal Medicine, University College London, London, United Kingdom of Great Britain and Northern Ireland
View PDF
Abstract
Background In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes.
Methods In this prespecified analysis of dapagliflozin's effects in patients with stage 4 CKD (eGFR